Account wins

Share this article:

MedAccess, a division of Access Communications, has been named agency of record for Stiefel Laboratories, brought on board to help with the launch of skin-care products, Extina and RevalèSkin. Extina was recently FDA approved for the topical treatment of seborrheric dermatitis, a chronic, recurrent skin condition that affects about five percent of the country's population. Extina is administered via VersaFoam HF, which studies show offers consistent skin permeation, drug distribution and drug delivery. This easy-to-use drug also absorbs quickly and is non-drying with no residue. RevalèSkin is the first and only professional anti-aging skin care line formulated with 1% CoffeeBerry, a natural super-antioxidant.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.